Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2016

01-02-2016 | Research Article

Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients

Authors: L.-R. Zhu, J. Li, P. Chen, Q. Jiang, X.-P. Tang

Published in: Clinical and Translational Oncology | Issue 2/2016

Login to get access

Abstract

Purpose

Elevated plasma fibrinogen and D-dimer levels indicate activation of hemostasis and fibrinolysis, and this activation is required for tumor angiogenesis, metastasis, and invasion. Previous studies demonstrated that the plasma fibrinogen and D-dimer levels correlate with patient’s prognosis in several solid tumors. The aim of this study is to examine the relationship between plasma fibrinogen and D-dimer levels before and during chemotherapy and treatment response and survival in patients with small cell lung cancer (SCLC).

Methods

Plasma fibrinogen and D-dimer levels before and during chemotherapy were prospectively measured in 74 SCLC patients who received first-line therapy. The results were analyzed for correlation between fibrinogen and D-dimer levels and treatment response, as well as progressive-free survival (PFS) and overall survival (OS).

Results

The levels of fibrinogen and D-dimer in SCLC patients before (C0) and after two cycles (C2) of chemotherapy were significantly higher than those in controls. Fibrinogen and D-dimer levels decreased during chemotherapy, and changes in fibrinogen and D-dimer levels between at C0 and at C2 were associated with treatment response. No matter which disease stage, patients with fibrinogen or D-dimer positivities at C0 and C2 time points had worse PFS and OS than those with fibrinogen or D-dimer negativities. Multivariate analyses revealed that fibrinogen and D-dimer positivities after two chemotherapy cycles were independently unfavorable factors for PFS and OS.

Conclusion

Fibrinogen and D-dimer levels after two cycles of chemotherapy are predictors for response on chemotherapy and prognosis in SCLC patients.
Literature
1.
Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G. Small cell lung cancer. Ann Oncol. 2006;17(suppl 2):ii5–10.CrossRefPubMed
2.
3.
Davies AM, Lara PN, Lau DH, Gandara D. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:373–85.CrossRefPubMed
4.
Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev. 2004;30:521–43.CrossRefPubMed
5.
Ma PC, Blaszkowsky L, Bharti A, Ladanya A, Kraeft S-K, Bruno A, et al. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer (Review). Anticancer Res. 2003;23:49–62.PubMed
6.
Buccheri G, Ferrigno D. Prognostic factors of small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:455–60.
7.
Bremnes RM, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomized multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39:303–13.CrossRefPubMed
8.
Li J, Dai C-H, Chen P, Wu J-N, Bao Q-L, Qiu H, et al. Survival and prognostic factors in small cell lung cancer. Med Oncol. 2010;27:73–8.CrossRefPubMed
9.
Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64:8613–9.CrossRefPubMed
10.
Palumbo JS, Talmage KE, Massari JV, LaJeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natured killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85.CrossRefPubMed
11.
Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumor cells. Best Pract Res Clin Heamatol. 2009;22:46–60.
12.
Kvoliks S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surg Oncol. 2010;19:33–46.CrossRef
13.
14.
Bluft JE, Brown NJ, Reed MWR, Staton CA. Tissue factor, angiogenesis and tumor progression. Breast Cancer Res. 2008;10:204.CrossRef
15.
Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002;62:6966–72.PubMed
16.
Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302–9.PubMed
17.
Yamashita H, Kitaya J, Kanno N, Yatomi Y, Nagawa H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer. 2006;6:147–53.PubMedCentralCrossRefPubMed
18.
Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22:2222–7.CrossRefPubMed
19.
Polterauer S, Seebacher V, Hefler-Frischuth K, Grimm C, Heinze G, Tempfer C, et al. Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol. 2009;200(647):el–7.
20.
Tsimafeyeu IV, Demidov LV, Madzhuga AV, Somonova OV, Yelizarova AL. Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. J Exp Clin Cancer Res. 2009;28:30.PubMedCentralCrossRefPubMed
21.
Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haemetologica. 2012;97:1158–63.CrossRef
22.
Dirix LX, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389–95.PubMedCentralCrossRefPubMed
23.
Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-Dimer levels are better predictor of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101:77–82.CrossRefPubMed
24.
Kwon H-C, Oh S-Y, Lee S, Kim S-H, Ha JY, Koh RY, et al. Plasma levels of prothrombin fragment F1 + 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38:2–7.CrossRefPubMed
25.
Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, et al. Increase in quantitative D-Dimer levels correlated with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Am J Clin Pathol. 2010;134:964–9.CrossRefPubMed
26.
Jones JM, McGonigle NC, McAnespie M, Cran GW, Craham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006;53:97–101.CrossRefPubMed
27.
Zhao J, Zhao M, Jin B, Yu P, Hu X, Teng Y. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer. 2012;12:330.PubMedCentralCrossRefPubMed
28.
Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, et al. High plasma D-dimer levels is associated with decreased survival in patients with lung cancer. Clin Oncol. 2007;19:494–8.CrossRef
29.
Tas F, Killic L, Serilmez M, Keskin S, Sen F, Durangiloiz D, et al. Clinical and prognostic significance of coagulation assay in lung cancer. Respir Med. 2013;107:451–7.CrossRefPubMed
30.
Antonion D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53:205–10.CrossRef
31.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMed
32.
Sheng L, Luo M, Sun X, Lin N, Mao W, Su D. Serum fibrinogen is an independent prognostic factor in operable non-small cell lung cancer. Int J Cancer. 2013;133:2720–5.CrossRefPubMed
33.
Palumbo JS, Degen JL. Hemostatic factors in tumor biology. J Pediatr Hematol Oncol. 2000;22:281–7.CrossRefPubMed
Metadata
Title
Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients
Authors
L.-R. Zhu
J. Li
P. Chen
Q. Jiang
X.-P. Tang
Publication date
01-02-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1350-7

Other articles of this Issue 2/2016

Clinical and Translational Oncology 2/2016 Go to the issue

Research Article

Expression and clinical significance of cortactin protein in ovarian neoplasms

Research Article

Targeting thiamine-dependent enzymes for metabolic therapies in oral squamous cell carcinoma?

Research Article

Pemetrexed for primary central nervous system lymphoma in the elderly

Research Article

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

Research Article

Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma

Research Article

A cross-sectional assessment of quality of life of colorectal cancer patients in Saudi Arabia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits